Markets

Tartisan Nickel Corp. has secured $1.3 million in flow-through financing to advance its Kenbridge Nickel-Copper-Cobalt Project in Ontario. The funds will fuel exploration and development activities, targeting critical minerals essential for the green economy. This financing highlights investor confidence and positions Tartisan to potentially unlock the project’s full value.

Nutex Health has opened its 26th facility, Archview ER & Hospital, in St. Louis, Missouri, marking its entry into the state. This new micro-hospital offers 24/7 emergency and inpatient care with advanced diagnostics, expanding Nutex Health’s network to 12 states. The move signifies the company’s strategy to increase access to its efficient, localized healthcare model.

Oversonic Robotics will deploy its RoBee cognitive humanoid robots at STMicroelectronics’ semiconductor manufacturing facilities. This partnership marks the first operational use of cognitive humanoids in the semiconductor industry, aiming to enhance efficiency, safety, and human-robot collaboration in complex production environments. The collaboration will be showcased at CES.

The FDA has approved Lunsumio VELO™, a subcutaneous formulation, for relapsed or refractory follicular lymphoma patients who have failed two or more prior therapies. This novel treatment offers a significantly reduced administration time, transforming from a hours-long infusion to a one-minute injection. This advancement aims to decrease patient burden and increase treatment flexibility, with a fixed-duration schedule potentially as short as six months. The approval is based on promising efficacy data, including a high objective response rate and a manageable safety profile, with ongoing research exploring its use in earlier lines of therapy.

Faraday Future has rolled out its first FX Super One pre-production MPV, signaling a strategic shift to an “Embodied AI” focus. This milestone validates the company’s production capabilities and sets the stage for a mass-market push. Faraday Future will unveil product roadmaps and sales strategies at CES, aiming to disrupt the U.S. market with innovative, AI-integrated electric vehicles and bridge Web2 and Web3 technologies.

Nidec Corporation is undergoing a leadership transition, with founder Shigenobu Nagamori stepping down as Chairman to become Chairman Emeritus. CEO Mitsuya Kishida will now also serve as Chairman of the Board. This move aims to ensure a smooth transfer of vision and leverage Nagamori’s experience while Kishida leads the company through rapid technological changes in sectors like automotive electrification and data centers.

Allied Gold has started Phase 1 fresh ore processing at its Sadiola mine, aiming to increase annual gold production by 17-30% to 200,000-230,000 ounces by Q1 2026. Further upgrades in 2026 will boost capacity and efficiency, with a Phase 2 expansion planned by 2029 to extend mine life. The company reaffirmed its 2023 production guidance, projecting over 375,000 ounces.

Telix Pharmaceuticals reports significant progress in its precision medicine portfolio, especially in oncology. Key advancements include positive Phase 3 data for TLX591-CDx (Illuccix®) in China for prostate cancer imaging, meeting its primary endpoint and paving the way for a Chinese NDA submission. The company is also nearing NDA resubmission for TLX101-CDx (Pixclara®) in the U.S. and has aligned with the FDA on CMC deficiencies for TLX250-CDx (Zircaix®) BLA. These developments highlight Telix’s strategic focus on radiopharmaceutical innovation and market expansion.

Clearwater Analytics is being acquired for $8.4 billion by an investor group led by Permira and Warburg Pincus, with participation from Temasek and support from Francisco Partners. This transaction offers Clearwater shareholders $24.55 per share in cash, a significant premium. The move to a private company is expected to accelerate Clearwater’s growth and innovation, particularly in developing a comprehensive front-to-back investment management solution. The deal is anticipated to close in the first half of 2026.

Rocket Lab concluded 2025 with a flawless Electron launch of iQPS’s QPS-SAR-15 satellite, marking a company record of 21 launches with 100% success. This mission enhanced iQPS’s SAR constellation, reinforcing Electron’s role as their primary launch vehicle. Rocket Lab plans further constellation deployments and defense missions in 2026, solidifying its position in the small satellite market.